43.1 2020 Year in Review: Advances in Fatty Liver Disease Drugs and Diagnostics
Send us a text Vlad Ratziu discusses a "boiling hot" field of emerging NASH drugs and "particularly rich" data coming from no-invasive diagnostic testing. Despite elafibranor failing, obeticholic acid not securing FDA approval and COVID-19 related limitations in the conduct of clinical trials, "this was a very good year actually for NASH clinical trials," with "some significant advances in terms of therapeutics for NASH" and . We had the results of several trials this year. We had the unfold...
25 Des 202023min
2020 Year-End NASH Review 1: Drugs and Diagnostics - Ep 43
Send us a text The Surfers and guests Vlad Ratziu and Mazen Noureddin discuss key lessons learned in 2020 about Drugs and Diagnostics. Vlad Ratziu and Mazen Noureddin join the Surfers to explore some of the key lessons learned and issues uncovered in 2020. Vlad Ratziu provides a 10-minute overview of a fast-paced year of successes (and occasional failures) in clinical trials and novel diagnostics. Mazen Noureddin discusses the expanding role of non-invasive liver tests in diagnosis, patient ...
24 Des 20201h 17min
Policy 2: Credibility, Convergence and the 2021 Global Liver Institute Action Plan - Ep 42
Send us a text Donna Cryer and Global Liver Institute Director of Policy Andrew Scott return to discuss their 2021 US NASH Action Plan, garnering support for the new COVID-19 vaccines and the importance of aligning stakeholders with Stephen, Louise and Roger. The Surfers end the year on an optimistic note by talking with sometime-surfer Donna Cryer and GLI Director of Policy Andrew Scott about GLI's ambitious 2021 US NASH Action Plan, which should be released by the time you read this. The p...
17 Des 202048min
Policy 1: The Liver Policy Agenda Has Experienced Surprising Success in the Last Four Years - Ep 41
Send us a text Donna Cryer and Global Liver Institute Director of Policy Andrew Scott join Stephen, Louise and Roger to discuss the policy progress liver disease and NASH have made in the last four years. This is the first of two epiodes discussing Public Policy questions that affect how stakeholders view NAFLD andNASH as a disease as well as the process by which related drugs and diagnostics are evaluated. Today's episode addresses the many kinds of progress that liver policy has made in th...
10 Des 20201h 1min
Links between NAFLD and Cardiovascular Disease - Ep 40
Send us a text Dr Ian Rowe and Prof. Dr. Jörn M. Schattenberg joins the Surfers to explore the relationship between NAFLD and CVD in light of recent work questioning the strength of links between the two This episode asks how to reconcile results from a presentation at EASL suggesting that the primary cause of death from NAFLD patients is liver disease and the low level of CVD events in the STELLAR-3 and STELLAR-4 trials with significant other data identifying CVD as the leading cause of dea...
3 Des 202048min
COVID CHAOS: The 2nd Wave - Ep 39
Send us a text Guest Ian Rowe and Dr. Kris Kowdley join the Surfers to discuss how the 2nd COVID wave and arrival of the vaccine are likely to affect patient treatment and clinical development. In Episode 39, hepatologists Ian Rowe and Kris Kowdley, who divide their time more or less evenly between patient clinics and clinical trials, join the Surfers to discuss how the Second Wave of COVID-19 will affect patient treatment and clinical trials. This conversation turns conventional wisdom on i...
24 Nov 202052min
The Day After TLMdX 2020 Wrapping Up with The View from Across the Atlantic - Ep 38
Send us a text Prof. Vlad Ratziu, MD, and Prof. Dr. Jörn M. Schattenberg join the Surfers to wrap up our conversation about this year's AASLD meeting. Prof. Dr. Jörn M. Schattenberg erg and Prof. Vlad Ratziu, MD join the Surfers for our wrap-up episode for TLMdX 2020. Joern focuses on a diabetes poster demonstrating the path of drug efficacy over a three-year period, while Vlad focuses on the successful Phase 2 trial of the pan-PPAR lanifibranor. The group also asks why placebo r...
19 Nov 202058min
Day Four of TLMdX 2020 - Monday at the Digital Liver Meeting -- Getting Better at Diagnostics and Drugs, Not Education - Ep 37
Send us a text The Surfers spend the final day of AASLD 2020 looking at two very different sets of issues. Issue 1: challenges proving efficacy in F2 populations, particularly in terms of fibrosis. Issue 2: social burdens of poor dietary choices around the world, particularly given how developing PNAFLD (pediatric non-alcoholic fatty liver disease) can create a metabolic burden that can last a lifetime. In the end, the group remained optimistic about the explosion of knowledge around drugs an...
17 Nov 20201h 15min
